Bisacodyl Therapy for Chronic Constipation

Mechanism of Action and Efficacy

The American Gastroenterological Association recommends bisacodyl for chronic idiopathic constipation with a strong recommendation and moderate certainty of evidence, as it increases complete spontaneous bowel movements by 2.54 per week and spontaneous bowel movements by 4.04 per week compared to placebo 1
Bisacodyl improves stool consistency, moving from hard to soft/well-formed consistency, with an improvement of 2.4 points on the Bristol Stool Form Scale 1
The American College of Gastroenterology guidelines position bisacodyl as a first-line option for occasional use or rescue therapy, with a recommended dose of 5-10 mg daily 1, 2

The American Gastroenterological Association recommends starting with lower doses of bisacodyl (5 mg orally) and titrating upward as tolerated to minimize adverse effects, with a maximum oral dose of 10 mg daily 1, 3
Bisacodyl is well-tolerated, but common adverse effects include diarrhea, abdominal pain/cramping, and electrolyte imbalances, which can be mitigated by ensuring adequate hydration throughout treatment 3
The American College of Gastroenterology guidelines recommend monitoring patients closely for signs of dehydration, severe abdominal pain, or electrolyte disturbances 3

Bisacodyl is contraindicated in patients with ileus, intestinal obstruction, severe dehydration, acute inflammatory bowel conditions, recent colorectal or gynecological surgery, and recent anal or rectal trauma 3, 4
The American Gastroenterological Association recommends avoiding bisacodyl in immunocompromised patients (neutropenic or thrombocytopenic) and in patients with severe or persistent abdominal pain 4

The 2023 American Gastroenterological Association–American College of Gastroenterology joint guidelines issue a strong recommendation (moderate‑certainty evidence) for using bisacodyl as short‑term or rescue therapy in adults with chronic idiopathic constipation. 5

In randomized trials, bisacodyl increased complete spontaneous bowel movements by ≈ 2.5 per week and total spontaneous bowel movements by ≈ 4 per week versus placebo, with a 2.4‑point improvement on the Bristol Stool Form Scale for stool consistency. 5

Bisacodyl is generally well‑tolerated, with mostly mild adverse effects such as abdominal pain, cramping, and diarrhea; these can be minimized by initiating therapy at lower doses and ensuring adequate hydration. 5

Short‑term use is defined as daily administration for four weeks or less; intermittent use as a rescue agent is acceptable for occasional constipation episodes. 5
If constipation persists beyond four weeks of bisacodyl therapy, patients should be referred for further evaluation and consideration of alternative agents such as osmotic laxatives (e.g., polyethylene glycol) or prescription‑level therapies. 5

Fiber supplements and stool softeners (e.g., docusate) are not recommended as first‑line therapy for chronic idiopathic constipation because fiber may aggravate symptoms in some individuals and docusate has not demonstrated benefit in clinical trials. 6